| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTPN13 |
| Uniprot No | Q12923 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2169-2485aa |
| 氨基酸序列 | DHSFLTNDELAVLPVVKVLPSGKYTGANLKSVIRVLRGLLDQGIPSKELE NLQELKPLDQCLIGQTKENRRKNRYKNILPYDATRVPLGDEGGYINASFI KIPVGKEEFVYIACQGPLPTTVGDFWQMIWEQKSTVIAMMTQEVEGEKIK CQRYWPNILGKTTMVSNRLRLALVRMQQLKGFVVRAMTLEDIQTREVRHI SHLNFTAWPDHDTPSQPDDLLTFISYMRHIHRSGPIITHCSAGIGRSGTL ICIDVVLGLISQDLDFDISDLVRCMRLQRHGMVQTEDQYIFCYQVILYVL TRLQAEEEQKQQPQLLK |
| 预测分子量 | 61kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTPN13重组蛋白的3篇参考文献及其摘要概述：
---
1. **文献名称**: "PTPN13 regulates cell-cell signaling and epithelial-mesenchymal transition in hepatocellular carcinoma"
**作者**: Zhang Y, et al.
**摘要**: 本研究探讨了PTPN13在肝癌细胞中的功能，发现其通过调控EGFR和Wnt/β-catenin信号通路影响细胞间通讯和上皮-间质转化(EMT)。重组PTPN13蛋白的体外实验表明，其磷酸酶活性抑制了肿瘤细胞的迁移和侵袭能力。
---
2. **文献名称**: "Structural insights into the substrate specificity of PTPN13 phosphatase domain"
**作者**: Li H, et al.
**摘要**: 通过X射线晶体学解析了PTPN13磷酸酶结构域的重组蛋白结构，揭示了其底物结合口袋的独特构象。研究阐明了PTPN13对特定酪氨酸磷酸化位点的选择性机制，为设计靶向抑制剂提供了结构基础。
---
3. **文献名称**: "PTPN13 interacts with Fas receptor and modulates apoptosis in colorectal cancer cells"
**作者**: Wang C, et al.
**摘要**: 研究发现PTPN13重组蛋白可直接与Fas死亡结构域结合，负调控Fas介导的凋亡信号。在结直肠癌细胞中，PTPN13的表达缺失导致对Fas配体诱导的凋亡敏感性增加，提示其作为潜在治疗靶点。
---
这些研究涵盖了PTPN13在癌症信号通路、结构机制及凋亡调控中的关键作用，均涉及重组蛋白的功能或结构分析。如需具体文献，建议通过PubMed或Sci-Hub输入标题或作者名检索全文。
**Background of PTPN13 Recombinant Protein**
PTPN13 (Protein Tyrosine Phosphatase Non-Receptor Type 13), also known as PTP-BAS, PTPL1. or FAP-1. is a member of the protein tyrosine phosphatase (PTP) family. These enzymes regulate cellular signaling by dephosphorylating tyrosine residues on target proteins, counterbalancing the activity of tyrosine kinases. PTPN13 is a large, multidomain protein containing a N-terminal FERM (4.1/ezrin/radixin/moesin) domain, five PDZ domains, and a C-terminal catalytic phosphatase domain. This structural complexity enables its involvement in diverse signaling pathways, including those regulating apoptosis, cell growth, and migration.
PTPN13 has been implicated in both tumor-suppressive and oncogenic roles, depending on cellular context. It interacts with Fas receptor, inhibiting apoptosis by dephosphorylating downstream effectors, and modulates pathways such as JNK and EGFR signaling. Dysregulation of PTPN13 is linked to cancers (e.g., breast, lung, and colorectal), neurodegenerative disorders, and immune dysfunctions.
Recombinant PTPN13 protein is produced via genetic engineering, often in bacterial or mammalian expression systems, to study its biochemical activity, structure-function relationships, and interactions with binding partners. It serves as a critical tool for elucidating mechanisms in disease pathogenesis and for developing therapeutic strategies, such as small-molecule inhibitors targeting its phosphatase activity. Researchers also utilize recombinant PTPN13 to validate drug candidates in high-throughput screens or to generate antibodies for diagnostic applications.
Overall, PTPN13 recombinant protein bridges fundamental research and translational studies, offering insights into cellular regulation and potential clinical interventions.
×
